Biologics in the management of pediatric inflammatory bowel disease: When and what to choose

Figure 2 Therapeutic drug monitoring in a child on biologics. Infliximab and adalimumab are generally not abandoned unless drug concentration is ≥ 10 μg/mL. Target higher drug levels in fistulizing perianal disease. LOR: Loss of response; TDM: Therapeutic drug monitoring; IM: Immunomodulator; ¹Arrow: In those at risk of increased drug clearance.